ANDA 88294, held by Hospira. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 88294 (Lidocaine Hydrochloride), held by Hospira, was first approved by FDA on May 16, 1984, with 8 approved supplements and 0 published complete response letters.
Indications and Usage Lidocaine Hydrochloride Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 16, 1984 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Mar 19, 2020 | Supplement 25Labeling · Standard review | Approved | None posted |
| Mar 19, 2020 | Supplement 23Labeling · Standard review | Approved | None posted |
| Apr 16, 2010 | Supplement 14Labeling | Approved | None posted |
| Oct 3, 1996 | Supplement 8Manufacturing | Approved | None posted |
| Sep 17, 1990 | Supplement 6Labeling | Approved | None posted |
| Dec 12, 1988 | Supplement 3Labeling | Approved | None posted |
| Aug 1, 1986 | Supplement 2Manufacturing | Approved | None posted |
| Apr 17, 1985 | Supplement 1Manufacturing | Approved | None posted |
| May 16, 1984 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters